Metabolic, kidney and liver
Islet replacement, immune modulation and organ-support claims are distinct research programmes. Commercial packages often blur them into a single promise of renewed organ function.
What the registry pattern says
Cirrhosis has the largest MSC registry footprint in this group (62 query results; 5 recruiting in the stored snapshot). Cirrhosis has the largest exosome footprint (4). These are query-result counts, not deduplicated patients or proof of benefit.
Verify whether the product replaces a missing cell function, targets inflammation or merely reports a laboratory marker. Transplant eligibility and established care remain separate decisions.
Condition × therapy-class snapshot
| Condition | MSC | MSC recruiting | HSCT-family | Exosomes |
|---|---|---|---|---|
| Chronic Kidney Disease | 0 | 0 | 0 | 0 |
| Cirrhosis | 62 | 5 | 21 | 4 |
| Diabetes | 29 | 1 | 14 | 1 |
Source: ClinicalTrials.gov API v2 stored snapshot. Category totals add query results and may contain overlapping studies; use condition pages for interpretation.
Interactive/editorial page by the StemCellAtlas research team. Where registry or literature counts appear, they use the dated 2026-08-29 snapshot. Browser-only tools do not send or store answers. Page generated 2026-08-29. See our editorial standards.